Payment overview · 2025
General Payments
$16,327.01
73 reported records · 27 companies
Healthcare provider profile · identity verified
Rohan Gupta, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · BURLESON, TX · NPI 1326482860
Verified facts
What the public records show
CMS Open Payments records show Rohan Gupta, DO received $16,327.01 in general payments during 2025 across 73 reported records.
Merck Sharp & Dohme LLC accounted for 39.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brukinsa, Jakafi, Venclexta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Venclexta by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 54 records involving 52 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ibrance by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 29 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Orgovyx by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Calquence by this doctor in 2024.
BeOne Medicines USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 10251 records involving 4941 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brukinsa by this doctor in 2024.
BeiGene USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 2084 records involving 1673 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brukinsa by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Pomalyst by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRYCEL as an associated drug or biological on 32 records involving 32 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Sprycel by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Promacta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ibrance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 16373 records involving 6981 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Orgovyx by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $6,405.12 | 39.2% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $3,920.02 | 24.0% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,675.00 | 10.3% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $1,475.18 | 9.0% | 5 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $1,387.50 | 8.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $246.18 | 1.5% | 12 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $153.48 | 0.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $152.42 | 0.9% | 8 | 2025 |
| Avita Medical Americas, LLC | Unresolved — no canonical attribution shown | $151.04 | 0.9% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $129.44 | 0.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $89.99 | 0.6% | 4 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $72.15 | 0.4% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $66.47 | 0.4% | 3 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $54.59 | 0.3% | 2 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $43.80 | 0.3% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $32.86 | 0.2% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $32.83 | 0.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.15 | 0.2% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $28.68 | 0.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $28.37 | 0.2% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $27.57 | 0.2% | 1 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $24.47 | 0.1% | 1 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $23.91 | 0.1% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $20.50 | 0.1% | 1 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.00 | 0.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.89 | 0.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.40 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $8,275.00 | 6 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,770.00 | 1 |
| Food and Beverage | $1,725.26 | 60 |
| Travel and Lodging | $1,520.35 | 4 |
| Education | $36.40 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $6,405.12 | 7 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $3,875.50 | 5 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $1,675.00 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $1,466.04 | 4 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $1,420.36 | 2 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $153.48 | 2 | 2025 |
Source payment records
|
|||||
| Cohealyx Normalized: cohealyx |
Device | Avita Medical Americas, LLC | $151.04 | 1 | 2025 |
Source payment records
|
|||||
| Permeaderm Normalized: permeaderm |
Device | Avita Medical Americas, LLC | $151.04 | 1 | 2025 |
Source payment records
|
|||||
| Recell Normalized: recell |
Device | Avita Medical Americas, LLC | $151.04 | 1 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $135.45 | 7 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $129.44 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $110.73 | 5 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $110.73 | 5 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $106.44 | 6 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $54.59 | 2 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $54.59 | 2 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $54.59 | 2 | 2025 |
Source payment records
|
|||||
| XALKORI Normalized: xalkori |
Drug | ARRAY BIOPHARMA INC | $54.59 | 2 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $50.50 | 2 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $45.98 | 2 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $45.51 | 2 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $43.80 | 2 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $33.50 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $32.83 | 2 | 2025 |
Source payment records
|
|||||
| Padcev Normalized: padcev |
Drug | Astellas Pharma US Inc | $29.15 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $28.68 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $27.57 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| Odomzo Normalized: odomzo |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| YONSA Normalized: yonsa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| CABLIVI Normalized: cablivi |
Biological | GENZYME CORPORATION | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| HYMPAVZI Normalized: hympavzi |
Drug | PFIZER INC. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeiGene USA, Inc. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $9.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRUKINSA brukinsa |
2025 | Brukinsa | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 52 recipient NPIs · example record 1228804288 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 26 recipient NPIs · example record 1228888885 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| BeOne Medicines USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 10251 supporting records · 4941 recipient NPIs · example record 1202883638 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| BeiGene USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 2084 supporting records · 1673 recipient NPIs · example record 1202877750 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 29 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 29 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | SPRYCEL open payments reported associated product |
CMS Open Payments — General Payments 32 supporting records · 32 recipient NPIs · example record 1184390211 |
Sprycel · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 16373 supporting records · 6981 recipient NPIs · example record 1228794230 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 337 | 108 |
| Eliquis | Apixaban | 110 | 29 |
| Ondansetron Odt | Ondansetron | 106 | 82 |
| Abiraterone Acetate | Abiraterone Acetate | 94 | 11 |
| Prednisone | Prednisone | 85 | 26 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 84 | 67 |
| Revlimid | Lenalidomide | 79 | suppressed |
| Gabapentin | Gabapentin | 61 | 20 |
| Acyclovir | Acyclovir | 60 | 23 |
| Morphine Sulfate Er | Morphine Sulfate | 60 | 26 |
| Pomalyst | Pomalidomide | 49 | suppressed |
| Furosemide | Furosemide | 45 | 25 |
| Anastrozole | Anastrozole | 41 | 13 |
| Hydroxyurea | Hydroxyurea | 40 | 11 |
| Tramadol Hcl | Tramadol Hcl | 35 | 27 |
| Dexamethasone | Dexamethasone | 34 | 20 |
| Calquence | Acalabrutinib Maleate | 32 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 31 | 21 |
| Alprazolam | Alprazolam | 30 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 28 | 16 |
| Potassium Chloride | Potassium Chloride | 28 | 16 |
| Venclexta | Venetoclax | 28 | suppressed |
| Promacta | Eltrombopag Olamine | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | 21 |
| Sprycel | Dasatinib | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 21 | suppressed |
| Lenalidomide | Lenalidomide | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Brukinsa | Zanubrutinib | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Voriconazole | Voriconazole | 18 | suppressed |
| Lisinopril | Lisinopril | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Sancuso | Granisetron | 13 | suppressed |
| Vonjo | Pacritinib Citrate | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Orgovyx | Relugolix | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 11 | suppressed |
| Ibrance | Palbociclib | 11 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nubeqa | Darolutamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16,327.01 · 73 records | Merck Sharp & Dohme LLC | ADCETRIS, BOSULIF, BRAFTOVI, BRUKINSA, CABLIVI, CABOMETYX, Cohealyx, DATROWAY, ELREXFIO, EPKINLY, FOTIVDA, FRUZAQLA, Fabhalta, HYMPAVZI, IMBRUVICA, IMFINZI, Indigo System, JAKAFI, JEMPERLI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LORBRENA, LUTATHERA, Lenvima, MEKTOVI, OGSIVEO, OJJAARA, Odomzo, Padcev, Permeaderm, REBLOZYL, Recell, Restrata Wound Matrix, SARCLISA, SCEMBLIX, TECVAYLI, TEVIMBRA, VENCLEXTA, Vanflyta, XALKORI, XT CDX, XTANDI, YONSA | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brukinsa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error